NRAS
About
Location: 1p13.2
Mappings
Biomarkers
NRAS is involved in the following curated biomarkers.
| Name | Biomarker type | Propositions | Statements |
|---|---|---|---|
| Wild type NRAS | Wild type | 7 | 8 |
Therapeutic response
Precision oncology relationships for therapeutic response involving this gene.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Cetuximab | |
| Sensitivity (+) | EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Cetuximab, Irinotecan | |
| Sensitivity (+) | EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Cetuximab, Fluorouracil, Oxaliplatin | |
| Sensitivity (+) | HER2-positive, Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Trastuzumab, Tucatinib | |
| Sensitivity (+) | Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Fluorouracil, Oxaliplatin, Panitumumab | |
| Sensitivity (+) | Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Fluorouracil, Irinotecan, Panitumumab | |
| Sensitivity (+) | Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Fluorouracil, Irinotecan, Panitumumab | |
| Sensitivity (+) | Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Panitumumab |